Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00470847 · ClinicalTrials.gov registry record · Phase 1
Lapatinib in Combination With Radiation Therapy in Patients With Brain Metastases From HER2-Positive Breast Cancer
A Phase 1 study, sponsored by Nancy Lin, MD.
- Completed
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
NCT00470847 is a Phase 1 study that has completed, run by Nancy Lin, MD. The registered enrollment target is 35 participants.
The verdict
NCT00470847, a Phase 1 study, has completed, sponsored by Nancy Lin, MD.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
Study Summary
The purpose of this research study is to determine the safety of combining lapatinib plus radiation in patients with breast cancer that has spread to the brain. Depending upon the participants cancer, they may also have stereotactic radiosurgery (SRS). Lapatinib s a compound that may stop cancer cells from growing abnormally. It is thought that lapatinib might also make cancer cells more sensitive to radiation. This drug has been used in other research studies in women with breast cancer, and information from those other research studies suggests that lapatinib may help to shrink or stabilize breast tumors both inside the brain and outside the brain.
Interventions
- DRUG Lapatinib
- DRUG Herceptin
- PROCEDURE Whole Brain Radiation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2007-04 |
| Est. Completion | 2012-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00470847
The ClinicalTrials.gov registry entry for NCT00470847 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nancy Lin, MD, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Lapatinib is the first listed.
NCT00470847 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00470847 about?
NCT00470847 is a clinical study titled "Lapatinib in Combination With Radiation Therapy in Patients With Brain Metastases From HER2-Positive Breast Cancer". The purpose of this research study is to determine the safety of combining lapatinib plus radiation in patients with breast cancer that has spread to the brain. Depending upon the participants cancer, they may also have stereotactic radiosurgery (SRS). Lapatinib s a compound that may stop cancer cel...
What is the current status of trial NCT00470847?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2007-04. Estimated completion is 2012-06.
What interventions are being tested in trial NCT00470847?
The interventions under investigation include: Lapatinib (DRUG), Herceptin (DRUG), Whole Brain Radiation (PROCEDURE).
Who is sponsoring clinical trial NCT00470847?
This trial is sponsored by Nancy Lin, MD, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.